This phase 2 trial tests a combination of two drugs—naxitamab (an antibody) and GM-CSF (an immune booster)—in children and adults with high-risk neuroblastoma that has not responded well to previous treatments. The goal is to see if this therapy can shrink or eliminate tumors in …
Phase: PHASE2 • Sponsor: Y-mAbs Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC